| Sep 19 |
Exelixis Faces 'Modest Growth' Prospects, Patent Risk With Limited Near-Term Upside, UBS Says
|
| Sep 18 |
A Closer Look at 5 Analyst Recommendations For Exelixis
|
| Sep 16 |
Exelixis unveils additional data on Cabometyx for neuroendocrine tumors
|
| Sep 16 |
Here's Why Exelixis (EXEL) is a Strong Value Stock
|
| Sep 16 |
Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss
|
| Sep 16 |
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
|
| Sep 15 |
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
|
| Sep 14 |
Exelixis, Inc. (EXEL): Among Hedge Funds’ Top Biotech Stock Picks
|
| Sep 5 |
Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?
|
| Sep 2 |
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
|
